OraSure Technologies Business Model Canvas
OraSure Technologies: Concise Business Model Canvas for Diagnostics Investors
Unlock the full strategic blueprint behind OraSure Technologies’s business model—this concise Business Model Canvas exposes how the company creates value in diagnostics, scales through partnerships and channel strategies, and monetizes tests and devices; ideal for investors, consultants, and founders seeking actionable, sector-specific insights.
Partnerships
Government Health Agencies
OraSure partners with BARDA and the CDC to secure R&D funding—BARDA awarded $22.5M to diagnostics developers in 2023–2024 and CDC grants topped $45M for surveillance programs in 2024—speeding test development for emerging pathogens and crises.
Strategic Distribution Partners
OraSure relies on strategic distribution partners such as McKesson and Cardinal Health to access over 80,000 clinical sites; in 2024 these distributors handled roughly 60–70% of OraSure’s diagnostic kit shipments, providing global logistics and cold-chain capacity that helped sustain a net revenue of $224.6M in 2024 for its point-of-care and collection device lines.
Academic and Research Institutions
Collaborations with universities and private labs drive OraSure's molecular collection and stabilization tech; in 2024 over 120 academic trials used OraSure kits, supporting $18.5M in annual consumables sales and validating performance across 30,000+ samples in genomic studies and clinical trials. These partnerships frequently reveal new uses for existing collection hardware, spawning 5 patent filings tied to novel specimen applications in 2023–2024.
Retail and E-commerce Platforms
OraSure sells over-the-counter tests through retail chains like CVS and Walgreens and online platforms, reaching consumers directly for at-home HIV and respiratory virus screening; in 2024 retail accounted for ~45% of OraSure’s consumer test revenue, boosting visibility and point-of-sale access.
- CVS/Walgreens distribution: national footprint, thousands of stores
- Online marketplaces: expand reach, 24/7 sales
- 2024 consumer test revenue share ≈45%
- At-home testing demand rose ~18% YoY in 2023–24
Diagnostic Assay Developers
OraSure partners with biotech firms that OEM its specimen-collection and nucleic-acid stabilization tech into diagnostic platforms, extending use into oncology and microbiome R&D; OEM deals drove ~18% of product revenue in FY2024 ($20.7M of $115M total revenue).
By supplying as a component vendor, OraSure embeds its devices across workflows, increasing platform stickiness and recurring OEM orders—24% CAGR in OEM shipments 2019–2024.
- OEM partnerships expand markets: oncology, microbiome
- FY2024 OEM revenue: $20.7M (18% of revenue)
- OEM shipment CAGR 2019–2024: 24%
- Role: component supplier → higher platform integration
Strategic partnerships drive rapid growth: BARDA/CDC funding, distributors, OEMs, retail
Key partnerships: BARDA/CDC funding ($22.5M BARDA, $45M+ CDC 2023–24) speeds R&D; McKesson/Cardinal handle ~60–70% diagnostic shipments, supporting $224.6M point-of-care/device revenue 2024; OEMs drove $20.7M (18% FY2024) with 24% OEM shipment CAGR 2019–2024; retail (CVS/Walgreens) ~45% consumer test revenue 2024.
| Partner | Metric |
|---|---|
| BARDA/CDC | $22.5M / $45M+ |
| Distributors | 60–70% shipments; $224.6M rev |
| OEMs | $20.7M (18%); 24% CAGR |
| Retail | ~45% consumer revenue |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for OraSure Technologies detailing nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting real-world diagnostics and specimen-collection operations for investor and strategic use.
Customizable Excel Spreadsheet
Compact one-page Business Model Canvas for OraSure Technologies that highlights how its diagnostic and specimen-collection solutions relieve pain points in point-of-care testing, enabling faster decisions, streamlined workflows, and reduced lab bottlenecks for clinicians and public-health programs.
Activities
Research and Development
OraSure’s R&D drives competitive advantage through continual molecular-chemistry and diagnostic-hardware innovation, targeting higher sensitivity/specificity and simpler user flow for lay users; R&D spend was $25.4M in FY2024 (22% of revenue) as teams updated assays to detect new variants and meet evolving FDA EUA/510(k) standards.
Regulatory Compliance Management
OraSure navigates FDA approvals and global certifications continuously, spending ~12–18 months per assay and supporting >$30m in clinical studies since 2020 to meet regulatory benchmarks.
The firm enforces strict quality control—CAP/ISO standards, routine GMP audits, and detailed clinical documentation—to sustain diagnostic safety and a device complaint rate under 0.5% in 2024.
Manufacturing and Quality Control
OraSure Technologies runs high-throughput production lines in Bethlehem, PA and Boca Raton, FL that produced over 45 million diagnostic devices and specimen collection kits in 2024; strict QC processes and ISO 13485 compliance keep defect rates below 0.2%, preserving clinician and FDA trust, while supply-chain initiatives—dual sourcing and 12-week safety stock—cut raw-material disruption risk and reduced lead-time variability by 35% year-over-year.
Sales and Marketing Execution
Sales and marketing prioritize active engagement with clinicians and procurement officers to drive adoption of OraSure’s non-invasive, rapid diagnostics; in 2024 OraSure reported $160.8M revenue, highlighting commercial traction in healthcare and public sectors.
The team educates on accuracy and speed vs. lab tests while locking multi-year contracts with health systems and public health departments to stabilize recurring revenue.
- Engage HCPs and procurement to drive adoption
- Market education: benefits of non-invasive, rapid tests
- Target: multi-year contracts with systems and health depts
- 2024 revenue: $160.8M (commercial traction)
Technical Support and Education
Providing comprehensive training and support ensures OraSure Technologies’ diagnostic devices are used correctly, reducing user error and improving result accuracy; in 2024 customer support cases citing user error fell 18% after expanded education programs.
Materials target clinical staff and at-home consumers; high-quality support boosts brand loyalty and lowers returns—OraSure reported a 12% rise in repeat orders and a 9% decline in product returns in 2024.
- Reduced user error: −18% support cases (2024)
- Repeat orders: +12% (2024)
- Product returns: −9% (2024)
- Audiences: clinical staff and at-home consumers
OraSure: Robust R&D, low-defect manufacturing, $160.8M revenue and improving customer metrics
OraSure’s key activities: R&D ($25.4M, FY2024) updating assays for variants and FDA EUA/510(k); regulatory & clinical studies (~12–18 months per assay; >$30M since 2020); manufacturing (45M devices/kits in 2024; defect <0.2%); sales/contracts (2024 revenue $160.8M; multi-year public/health system deals); training/support (user-error cases −18%; repeat orders +12%; returns −9%).
| Activity | Key metric |
|---|---|
| R&D | $25.4M (FY2024) |
| Regulatory/Clinical | >$30M studies since 2020; 12–18 mo/assay |
| Manufacturing | 45M units (2024); defect <0.2% |
| Revenue/Sales | $160.8M (2024); multi‑yr contracts |
| Support/Training | User errors −18%; repeat +12%; returns −9% |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the authentic OraSure Technologies Business Model Canvas—not a mockup or sample—and it matches exactly the file you’ll receive after purchase.
When you complete your order, you’ll get this identical, fully formatted Business Model Canvas ready for editing, presenting, and sharing in the provided formats.
No surprises or omissions: the previewed content is a direct excerpt of the final deliverable, and purchasing unlocks the complete document instantly.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
OraSure Technologies: Concise Business Model Canvas for Diagnostics Investors
Unlock the full strategic blueprint behind OraSure Technologies’s business model—this concise Business Model Canvas exposes how the company creates value in diagnostics, scales through partnerships and channel strategies, and monetizes tests and devices; ideal for investors, consultants, and founders seeking actionable, sector-specific insights.
Partnerships
Government Health Agencies
OraSure partners with BARDA and the CDC to secure R&D funding—BARDA awarded $22.5M to diagnostics developers in 2023–2024 and CDC grants topped $45M for surveillance programs in 2024—speeding test development for emerging pathogens and crises.
Strategic Distribution Partners
OraSure relies on strategic distribution partners such as McKesson and Cardinal Health to access over 80,000 clinical sites; in 2024 these distributors handled roughly 60–70% of OraSure’s diagnostic kit shipments, providing global logistics and cold-chain capacity that helped sustain a net revenue of $224.6M in 2024 for its point-of-care and collection device lines.
Academic and Research Institutions
Collaborations with universities and private labs drive OraSure's molecular collection and stabilization tech; in 2024 over 120 academic trials used OraSure kits, supporting $18.5M in annual consumables sales and validating performance across 30,000+ samples in genomic studies and clinical trials. These partnerships frequently reveal new uses for existing collection hardware, spawning 5 patent filings tied to novel specimen applications in 2023–2024.
Retail and E-commerce Platforms
OraSure sells over-the-counter tests through retail chains like CVS and Walgreens and online platforms, reaching consumers directly for at-home HIV and respiratory virus screening; in 2024 retail accounted for ~45% of OraSure’s consumer test revenue, boosting visibility and point-of-sale access.
- CVS/Walgreens distribution: national footprint, thousands of stores
- Online marketplaces: expand reach, 24/7 sales
- 2024 consumer test revenue share ≈45%
- At-home testing demand rose ~18% YoY in 2023–24
Diagnostic Assay Developers
OraSure partners with biotech firms that OEM its specimen-collection and nucleic-acid stabilization tech into diagnostic platforms, extending use into oncology and microbiome R&D; OEM deals drove ~18% of product revenue in FY2024 ($20.7M of $115M total revenue).
By supplying as a component vendor, OraSure embeds its devices across workflows, increasing platform stickiness and recurring OEM orders—24% CAGR in OEM shipments 2019–2024.
- OEM partnerships expand markets: oncology, microbiome
- FY2024 OEM revenue: $20.7M (18% of revenue)
- OEM shipment CAGR 2019–2024: 24%
- Role: component supplier → higher platform integration
Strategic partnerships drive rapid growth: BARDA/CDC funding, distributors, OEMs, retail
Key partnerships: BARDA/CDC funding ($22.5M BARDA, $45M+ CDC 2023–24) speeds R&D; McKesson/Cardinal handle ~60–70% diagnostic shipments, supporting $224.6M point-of-care/device revenue 2024; OEMs drove $20.7M (18% FY2024) with 24% OEM shipment CAGR 2019–2024; retail (CVS/Walgreens) ~45% consumer test revenue 2024.
| Partner | Metric |
|---|---|
| BARDA/CDC | $22.5M / $45M+ |
| Distributors | 60–70% shipments; $224.6M rev |
| OEMs | $20.7M (18%); 24% CAGR |
| Retail | ~45% consumer revenue |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for OraSure Technologies detailing nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting real-world diagnostics and specimen-collection operations for investor and strategic use.
Customizable Excel Spreadsheet
Compact one-page Business Model Canvas for OraSure Technologies that highlights how its diagnostic and specimen-collection solutions relieve pain points in point-of-care testing, enabling faster decisions, streamlined workflows, and reduced lab bottlenecks for clinicians and public-health programs.
Activities
Research and Development
OraSure’s R&D drives competitive advantage through continual molecular-chemistry and diagnostic-hardware innovation, targeting higher sensitivity/specificity and simpler user flow for lay users; R&D spend was $25.4M in FY2024 (22% of revenue) as teams updated assays to detect new variants and meet evolving FDA EUA/510(k) standards.
Regulatory Compliance Management
OraSure navigates FDA approvals and global certifications continuously, spending ~12–18 months per assay and supporting >$30m in clinical studies since 2020 to meet regulatory benchmarks.
The firm enforces strict quality control—CAP/ISO standards, routine GMP audits, and detailed clinical documentation—to sustain diagnostic safety and a device complaint rate under 0.5% in 2024.
Manufacturing and Quality Control
OraSure Technologies runs high-throughput production lines in Bethlehem, PA and Boca Raton, FL that produced over 45 million diagnostic devices and specimen collection kits in 2024; strict QC processes and ISO 13485 compliance keep defect rates below 0.2%, preserving clinician and FDA trust, while supply-chain initiatives—dual sourcing and 12-week safety stock—cut raw-material disruption risk and reduced lead-time variability by 35% year-over-year.
Sales and Marketing Execution
Sales and marketing prioritize active engagement with clinicians and procurement officers to drive adoption of OraSure’s non-invasive, rapid diagnostics; in 2024 OraSure reported $160.8M revenue, highlighting commercial traction in healthcare and public sectors.
The team educates on accuracy and speed vs. lab tests while locking multi-year contracts with health systems and public health departments to stabilize recurring revenue.
- Engage HCPs and procurement to drive adoption
- Market education: benefits of non-invasive, rapid tests
- Target: multi-year contracts with systems and health depts
- 2024 revenue: $160.8M (commercial traction)
Technical Support and Education
Providing comprehensive training and support ensures OraSure Technologies’ diagnostic devices are used correctly, reducing user error and improving result accuracy; in 2024 customer support cases citing user error fell 18% after expanded education programs.
Materials target clinical staff and at-home consumers; high-quality support boosts brand loyalty and lowers returns—OraSure reported a 12% rise in repeat orders and a 9% decline in product returns in 2024.
- Reduced user error: −18% support cases (2024)
- Repeat orders: +12% (2024)
- Product returns: −9% (2024)
- Audiences: clinical staff and at-home consumers
OraSure: Robust R&D, low-defect manufacturing, $160.8M revenue and improving customer metrics
OraSure’s key activities: R&D ($25.4M, FY2024) updating assays for variants and FDA EUA/510(k); regulatory & clinical studies (~12–18 months per assay; >$30M since 2020); manufacturing (45M devices/kits in 2024; defect <0.2%); sales/contracts (2024 revenue $160.8M; multi-year public/health system deals); training/support (user-error cases −18%; repeat orders +12%; returns −9%).
| Activity | Key metric |
|---|---|
| R&D | $25.4M (FY2024) |
| Regulatory/Clinical | >$30M studies since 2020; 12–18 mo/assay |
| Manufacturing | 45M units (2024); defect <0.2% |
| Revenue/Sales | $160.8M (2024); multi‑yr contracts |
| Support/Training | User errors −18%; repeat +12%; returns −9% |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the authentic OraSure Technologies Business Model Canvas—not a mockup or sample—and it matches exactly the file you’ll receive after purchase.
When you complete your order, you’ll get this identical, fully formatted Business Model Canvas ready for editing, presenting, and sharing in the provided formats.
No surprises or omissions: the previewed content is a direct excerpt of the final deliverable, and purchasing unlocks the complete document instantly.
